Vancouver, British Columbia, December 19, 2016 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for APC’s U.S. Patent Application Serial Number 14/400,190 titled “Site-Specific Labeling and Targeted Delivery of Proteins for the Treatment of Cancer”.

The application provides a number of examples of linked proteins that constitute novel molecular entities. They are designed to increase the potency as well as the duration of action, against tumor cells compared with the single, separate proteins that make up this new molecular entity. Certain members of this new class of compounds produced by APC have exhibited the ability to retard tumor growth in animal models, and reduce PD-L1 expression in cellular studies. It is to be noted that anti-PD-L1 agents have demonstrated marked clinical success in a wide range of malignancies by providing durable benefits with minimal toxicities and opened up novel avenues for cancer immunotherapy.

“This is a significant milestone for APC that strengthens our overall patent position and provides support for further applications of site specific labelling and the targeted delivery of proteins to cancer cells,” stated Dr. Allen Krantz, CEO of Advanced Proteome Therapeutics. “The compounds of the present invention stimulate the immune system. They represent additional weapons in APC’s arsenal against tumors, which include antibody-drug conjugates currently being pursued by the Company, and offer possibilities for combining both therapies for more effective treatments.”

This application includes claims intended to protect APC’s invention involving specific proteins that have been attached (linked) to other proteins and exhibit activity against tumor cells. As well, claims of a method for treating cancer in a patient, comprising administering to a patient an effective amount of the pharmaceutical composition of such linked proteins have been allowed.

About APC

Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates.


Advanced Proteome Therapeutics Corporation
Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: 617-638-0340

Advanced Proteome Therapeutics Corporation
Babak Pedram
Investor Relations
Virtus Advisory Group Inc.
Tel: 416-644-5081

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.